Wagner Heidi L sold $42K of WVE
Wagner Heidi L sold 7,000 shares of Wave Life Sciences, Inc. (WVE) at $6.01 on 2026-08-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the director’s sale size, price, and post-transaction holdings under a 10b5-1 plan; no new corporate event is described.
Market read
Traders may note the sale for sentiment monitoring, but there is no fundamental catalyst or guidance change in the text.
What to watch
Insider sales are common and often scheduled; without changes in other insiders, volume, or company disclosures, the trading signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Wave Life Sciences, Inc.
Ticker impact
Wave Life Sciences director Wagner Heidi L sold 7,000 shares at $6.01 under a pre-arranged 10b5-1 plan, per Form 4.
Low likelihood of a sustained price move solely from this Form 4 sale.
The filing is an open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.
Market effects
No sector-level implications; this is company-specific insider transaction reporting.
None indicated.
None indicated.
Counterpoint
A director sale can still reflect private information, but the presence of a 10b5-1 plan reduces interpretability.
Key entities
- issuerWave Life Sciences, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderWagner Heidi L
Director who sold 7,000 shares at $6.0100/share under a pre-arranged 10b5-1 plan.
